Biodistribution and dosimetry of 18F-EF5 in cancer patients with preliminary comparison of 18F-EF5 uptake versus EF5 binding in human glioblastoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 11, 2010, Pages 2048-2059

  Koch, Cameron J ^a   Scheuermann, Joshua S ^a   Divgi, Chaitanya ^a   Judy, Kevin D ^a   Kachur, Alexander V ^a   Freifelder, Richard ^a   Reddin, Janet S ^a   Karp, Joel ^a   Stubbs, James B ^b   Hahn, Stephen M ^a   Driesbaugh, Jason ^a   Smith, Deborah ^a   Prendergast, Susan ^a   Evans, Sydney M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Radiation Dosimetry Systems Inc   (United States)

Author keywords

18F EF5; Brain; EF5; Glioma; Hypoxia; Immunohistochemistry; Molecular imaging; PET

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE F 18; FLUORINE; FLUORODEOXYGLUCOSE F 18; TRACER; UNCLASSIFIED DRUG;

ADDITION REACTION; ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; DRUG URINE LEVEL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LIPOPHILICITY; MALE; POSITRON EMISSION TOMOGRAPHY; PRESSURE; RADIATION ABSORPTION; RADIATION EXPOSURE; SOFT TISSUE; WHOLE BODY SCANNER; WHOLE BODY SCINTISCANNING;

BIOLOGICAL TRANSPORT; BRAIN NEOPLASMS; CELL HYPOXIA; ETANIDAZOLE; FEMALE; FLUORINE RADIOISOTOPES; GLIOBLASTOMA; HUMANS; HYDROCARBONS, FLUORINATED; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 77958466808     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1517-y     Document Type: Article

References (54)

1. SM Evans CJ Koch 2003 Prognostic significance of tumor oxygenation in humans Cancer Lett 195 1 16 1:CAS:528:DC%2BD3sXktFWmsLs%3D 10.1016/S0304- 3835(03)00012-0 12767506
2. P Vaupel A Mayer 2007 Hypoxia in cancer: significance and impact on clinical outcome Cancer Metastasis Rev 26 225 239 1:CAS:528:DC%2BD2sXotFWrtLo%3D 10.1007/s10555-007-9055-1 17440684
3. JL Tatum GJ Kelloff RJ Gillies JM Arbeit JM Brown KSC Chao, et al. 2006 Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy Int J Radiat Biol 82 699 757 1:CAS:528:DC%2BD28XhtlejsbnM 10.1080/09553000601002324 17118889
4. GD Wilson 2007 Hypoxia and prognosis: the oxygen tension mounts Front Biosci 12 3502 3518 1:CAS:528:DC%2BD2sXms1KmtLk%3D 10.2741/2330 17485317
5. Koch CJ. Competition between radiation protectors and radiation sensitizers in mammalian cells. In: Nygaard OF, Simic MG, editors. Radioprotectors and anticarcinogens. New York: Academic; 1983. p. 275-96.
6. M Höckel C Knoop K Schlenger B Vorndran E Baussmann M Mitze, et al. 1993 Intratumor pO2 predicts survival in advanced cancer of the uterine cervix Radiother Oncol 26 45 50 10.1016/0167-8140(93)90025-4 8438086
7. DM Brizel SP Scully JM Harrelson LJ Layfield JM Bean LR Prosnitz, et al. 1996 Tissue oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma Cancer Res 56 941 943 1:CAS:528:DyaK28XhtlKks7Y%3D 8640781
8. M Nordsmark M Overgaard J Overgaard 1996 Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck Radiother Oncol 41 31 39 1:CAS:528:DyaK28XntlWiu78%3D 8961365
9. AW Fyles M Milosevic R Wong MC Kavanagh M Pintilie A Sun, et al. 1998 Oxygenation predicts radiation response and survival in patients with cervix cancer Radiother Oncol 48 149 156 1:CAS:528:DyaK1cXltlCjs7k%3D 10.1016/S0167-8140(98)00044-9 9783886
10. F Dehdashti PW Grigsby MA Mintun JS Lewis BA Siegel MJ Welch 2003 Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report Int J Radiat Oncol Biol Phys 55 1233 1238 12654432
11. W-J Koh JS Rasey ML Evans JR Grierson TK Lewellan MM Graham, et al. 1992 Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole Int J Radiat Oncol Biol Phys 22 199 212 1:STN:280:DyaK38%2FnvVSgsQ%3D%3D 1727119
12. KA Krohn JM Link RP Mason 2008 Molecular imaging of hypoxia J Nucl Med 49 129S 148S 1:CAS:528:DC%2BD1cXotFahu78%3D 10.2967/jnumed.107.045914 18523070
13. S-M Eschmann F Paulsen M Reimold H Dittmann S Welz G Reischl, et al. 2005 Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy J Nucl Med 46 253 260 15695784
14. D Thorwarth S-M Eschmann J Scheiderbauer F Paulsen M Alber 2005 Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer BMC Cancer 5 152 10.1186/1471-2407-5- 152 16321146
15. D Rischin RJ Hicks R Fisher D Binns J Corry S Porceddu, et al. 2006 Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2098 2104 10.1200/JCO.2005.05.2878 16648512
16. JR Ballinger 2001 Imaging hypoxia in tumors Semin Nucl Med 31 321 329 1:STN:280:DC%2BD3MnmsFSgtQ%3D%3D 10.1053/snuc.2001.26191 11710774
17. JD Chapman P Zanzonico CC Ling 2001 On measuring of hypoxia in individual tumors with radiolabeled agents J Nucl Med 42 1653 1655 1:CAS:528: DC%2BD38XktlOkt7c%3D 11696634
18. R Beck B Röper JM Carlsen MC Huisman JA Lebschi M Andratschke, et al. 2007 Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine J Nucl Med 48 973 980 1:CAS:528: DC%2BD2sXhtVert7fJ 10.2967/jnumed.106.038570 17536108
19. A-L Grosu M Souvatzoglou B Röper M Dobritz N Wiedenmann V Jacob, et al. 2007 Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer Int J Radiat Oncol Biol Phys 69 541 551 1:CAS:528:DC%2BD2sXhtVeqs7jP 17869667
20. CJ Koch AL Shuman WT Jenkins AV Kachur JS Karp R Freifelder, et al. 2009 The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake Int J Radiat Biol 85 1137 1147 1:CAS:528:DC%2BD1MXhsFent73K 10.3109/09553000903242172 19995239
21. CJ Koch SM Hahn KJ Rockwell JM Covey WK McKenna SM Evans 2001 Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3- pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo Cancer Chemother Pharmacol 48 177 187 1:CAS:528: DC%2BD3MXmsVCnt7k%3D 10.1007/s002800100324 11592338
22. CN Coleman RC Urtasun TH Wasserman S Hancock JW Harris J Halsey, et al. 1984 Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508 Int J Radiat Oncol Biol Phys 10 1749 1753 1:STN:280: DyaL2M%2Fgs1Gjuw%3D%3D 6237086
23. Koch CJ. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and the 2-nitroimidazole EF5. In: Sen CK, Packer L, editors. Methods in enzymology-antioxidants & redox cycling. San Diego: Academic; 2002. p. 3-31.
24. P Workman 1980 Pharmacokinetics of hypoxic cell radiosensitizers: a review Cancer Clin Trials 3 237 251 1:CAS:528:DyaL3cXlsVant7k%3D 7438321
25. CN Coleman J Halsey RS Cox K Hirst T Blaschke AE Howes, et al. 1987 Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile Cancer Res 47 319 322 1:CAS:528: DyaL2sXpvVKntw%3D%3D 3024818
26. EM Lord LW Harwell CJ Koch 1993 Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts Cancer Res 53 5721 5726 1:CAS:528:DyaK2cXhtVWju74%3D 8242628
27. PL Southwick LA Ernst EW Tauriello SR Parker RB Mujumdar SR Mujumdar, et al. 1990 Cyanine dye labeling reagents-carboxymethylindocyanine succinimidyl esters Cytometry 11 418 430 1:CAS:528:DyaK3MXit1Crtbw%3D 10.1002/cyto.990110313 2340776
28. SM Evans KD Judy I Dunphy WT Jenkins W-T Hwang PT Nelson, et al. 2004 Hypoxia is important in the biology and aggression of human glial brain tumors Clin Cancer Res 10 8177 8184 1:CAS:528:DC%2BD2cXhtFGjsrjM 10.1158/1078-0432.CCR- 04-1081 15623592
29. SM Evans KL Du AA Chalian R Mick PJ Zhang SM Hahn, et al. 2007 Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome Int J Radiat Oncol Biol Phys 69 1024 1031 17967299
30. Evans SM, Jenkins KW, Chen HI, Jenkins WT, Judy KD, Hwang W-T, et al. The relationship between hypoxia, proliferation and outcome in patients with de novo glioblastoma: a pilot study. Transl Oncol 2009; In press.
31. WR Dolbier A-R Li CJ Koch C-Y Shiue AV Kachur 2001 [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure Appl Radiat Isot 54 73 80 1:CAS:528:DC%2BD3cXotVKrtb8%3D 10.1016/S0969-8043(00)00102-0 11144255
32. LS Ziemer SM Evans AV Kachur AL Shuman CA Cardi WT Jenkins, et al. 2003 Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5 Eur J Nucl Med Mol Imaging 30 259 266 1:CAS:528:DC%2BD3sXms1CntQ%3D%3D 10.1007/s00259-002-1037-5 12552344
33. K Allemann MT Wyss M Wergin S Ohlerth C Rohrer-Bley SM Evans, et al. 2005 Measurements of hypoxia ([(18)F]-FMISO, [(18)F]-EF5) with positron emission tomography (PET) and perfusion using PET ([(15)O]-H(2)O) and power Doppler ultrasonography in feline fibrosarcomas Vet Comp Oncol 3 211 221 1:STN:280:DC%2BD1Mnis1WlsQ%3D%3D 10.1111/j.1476-5810.2005.00081.x 19754776
34. G Komar M Seppänen O Eskola P Lindholm JT Grönroos S Forsback, et al. 2008 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer J Nucl Med 49 1944 1951 10.2967/jnumed.108.053785 18997048
35. S Surti JS Karp 2004 Imaging characteristics of a 3-dimensional GSO whole-body PET camera J Nucl Med 45 1040 1049 1:CAS:528:DC%2BD2cXnsFygtro%3D 15181139
36. MG Stabin RB Sparks E Crowe 2005 OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine J Nucl Med 46 1023 1027 15937315
37. RJ Cloutier SA Smith EE Watson WS Snyder GG Warner 1973 Dose to the fetus from radionuclides in the bladder Health Phys 25 147 161 1:STN:280: DyaE2c7itl2nsA%3D%3D 10.1097/00004032-197308000-00009 4784245
38. SM Evans SM Hahn DP Magarelli PJ Zhang WT Jenkins DL Fraker, et al. 2001 Hypoxia in human intraperitoneal and extremity sarcomas Int J Radiat Oncol Biol Phys 49 587 596 1:CAS:528:DC%2BD3MXhtFegtLk%3D 10.1016/S0360-3016(00)01494-2 11173159
39. SM Evans KD Judy I Dunphy WT Jenkins PT Nelson R Collins, et al. 2004 Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding Cancer Res 64 1886 1892 1:CAS:528: DC%2BD2cXhslersrc%3D 10.1158/0008-5472.CAN-03-2424 14996753
40. SM Evans KW Jenkins WT Jenkins T Dilling KD Judy A Schrlau, et al. 2008 Imaging and analytical methods for the evaluation of vasculature and hypoxia in human brain tumors Radiat Res 170 677 690 1:CAS:528:DC%2BD1cXhsVKgtLnP 10.1667/RR1207.1 19138031
41. JJ Cascieri MM Graham JS Rasey 1995 A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data Med Phys 22 1127 1139 10.1118/1.597506
42. JG Rajendran DL Schwartz J O'Sullivan LM Peterson P Ng J Scharnhorst, et al. 2006 Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer Clin Cancer Res 12 5435 5441 1:CAS:528:DC%2BD28XpvFShsb4%3D 10.1158/1078-0432.CCR-05-1773 17000677
43. EJ Postema AJB McEwan TA Riauka P Kumar DA Richmond DN Abrams, et al. 2009 Initial results of hypoxia imaging using 1-alpha-D-(5-deoxy-5-[18F]- fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA) Eur J Nucl Med Mol Imaging 36 1565 1573 1:CAS:528:DC%2BD1MXht1WhtLrO 10.1007/s00259-009-1154-5 19430784
44. JA Raleigh CJ Koch 1990 Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules Biochem Pharmacol 40 2457 2464 1:CAS:528:DyaK3MXpslGiuw%3D%3D 10.1016/0006-2952(90)90086-Z 2176499
45. CJ Koch 2008 Importance of antibody concentration in the assessment of cellular hypoxia by flow cytometry: EF5 and pimonidazole Radiat Res 169 677 688 1:CAS:528:DC%2BD1cXmsFOgtrk%3D 10.1667/RR1305.1 18494550
46. SM Evans A Schrlau AA Chalian P Zhang CJ Koch 2006 Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding J Invest Dermatol 126 2596 2606 1:CAS:528:DC%2BD28Xht1Sgt7vL 10.1038/sj.jid.5700451 16810299
47. MM Graham LM Peterson JM Link ML Evans JS Rasey W-J Koh, et al. 1997 Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies J Nucl Med 38 1631 1636 1:CAS:528:DyaK2sXmvFGjtbc%3D 9379204
48. CJ Koch SM Evans 2003 Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles Adv Exp Med Biol 510 285 292 1:CAS:528:DC%2BD3sXns1ejsb0%3D 12580442
49. J Bergman O Solin 1997 Fluorine-18-labeled fluorine gas for synthesis of tracer molecules Nucl Med Biol 24 677 683 1:CAS:528:DyaK2sXmslCisrY%3D 10.1016/S0969-8051(97)00078-4 9352540
50. P Mahy X Geets M Lonneux P Levêque N Christian M De Bast, et al. 2008 Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism Eur J Nucl Med Mol Imaging 35 1282 1289 1:STN:280:DC%2BD1cznvFOhtw%3D%3D 10.1007/s00259-008-0742-0 18317752
51. JH Oppenheimer ML Levy U Sinha H el-Kadi ML Apuzzo G Luxton, et al. 1992 Radionecrosis secondary to interstitial brachytherapy: correlation of magnetic resonance imaging and histopathology Neurosurgery 31 336 343 1:STN:280:DyaK38zot1OnsQ%3D%3D 10.1227/00006123-199208000-00020 1513439
52. M De Saint-Hubert K Prinsen L Mortelmans A Verbruggen FM Mottaghy 2009 Molecular imaging of cell death Methods 48 178 187 10.1016/j.ymeth.2009.03.022 19362149
53. N Qayum RJ Muschel JH Im L Balathasan CJ Koch S Patel, et al. 2009 Tumor vascular changes mediated by inhibition of oncogenic signaling Cancer Res 69 6347 6354 1:CAS:528:DC%2BD1MXpt1Cgu7w%3D 10.1158/0008-5472.CAN-09-0657 19622766
54. RJ Nickles ME Daube TJ Ruth 1984 An 18O2 target for the production of [18F]F2 Int J Appl Radiat Isot 35 117 122 1:CAS:528:DyaL2cXhsVKqsbs%3D 10.1016/0020-708X(84)90194-7